AstraZeneca PLC (NASDAQ:AZN) Stock Position Increased by Callan Capital LLC

Callan Capital LLC lifted its position in AstraZeneca PLC (NASDAQ:AZN) by 103.9% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,358 shares of the company’s stock after buying an additional 5,277 shares during the period. Callan Capital LLC’s holdings in AstraZeneca were worth $808,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Ieq Capital LLC raised its position in shares of AstraZeneca by 32.1% during the second quarter. Ieq Capital LLC now owns 37,265 shares of the company’s stock worth $2,906,000 after purchasing an additional 9,059 shares during the period. XTX Topco Ltd acquired a new stake in shares of AstraZeneca during the second quarter worth $1,075,000. Hsbc Holdings PLC raised its position in shares of AstraZeneca by 750.3% during the second quarter. Hsbc Holdings PLC now owns 1,283,274 shares of the company’s stock worth $100,523,000 after purchasing an additional 1,132,362 shares during the period. Vanguard Personalized Indexing Management LLC raised its position in shares of AstraZeneca by 51.8% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 93,467 shares of the company’s stock worth $7,289,000 after purchasing an additional 31,893 shares during the period. Finally, Argent Trust Co raised its position in shares of AstraZeneca by 9.5% during the second quarter. Argent Trust Co now owns 7,136 shares of the company’s stock worth $557,000 after purchasing an additional 618 shares during the period. Institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on AZN. Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. Argus upped their price target on AstraZeneca from $80.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, May 30th. The Goldman Sachs Group began coverage on AstraZeneca in a research report on Thursday, May 30th. They set a “buy” rating and a $97.00 price target on the stock. Citigroup raised AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Finally, Barclays raised AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Stock Performance

Shares of NASDAQ AZN opened at $78.90 on Friday. The business’s 50-day moving average price is $81.80 and its two-hundred day moving average price is $76.46. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68. The company has a market capitalization of $244.63 billion, a P/E ratio of 38.68, a price-to-earnings-growth ratio of 1.49 and a beta of 0.47.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Thursday, July 25th. The company reported $0.99 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.01. The firm had revenue of $12.45 billion for the quarter, compared to the consensus estimate of $12.62 billion. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 earnings per share. Analysts anticipate that AstraZeneca PLC will post 4.05 earnings per share for the current fiscal year.

AstraZeneca Cuts Dividend

The business also recently declared a Semi-Annual dividend, which was paid on Monday, September 9th. Stockholders of record on Friday, August 9th were paid a dividend of $0.49 per share. The ex-dividend date was Friday, August 9th. This represents a dividend yield of 1.8%. AstraZeneca’s dividend payout ratio (DPR) is presently 48.04%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.